scholarly journals Validation of Performance of the Gen-Probe Human Immunodeficiency Virus Type 1 Viral Load Assay with Genital Swabs and Breast Milk Samples

2002 ◽  
Vol 40 (11) ◽  
pp. 3929-3937 ◽  
Author(s):  
D. DeVange Panteleeff ◽  
S. Emery ◽  
B. A. Richardson ◽  
C. Rousseau ◽  
S. Benki ◽  
...  
2005 ◽  
Vol 36 (4) ◽  
pp. 382-386 ◽  
Author(s):  
Ma. Tereza Alvarez-Muñoz ◽  
Silvia Zaragoza-Rodríguez ◽  
Othón Rojas-Montes ◽  
Gerardo Palacios-Saucedo ◽  
Guillermo Vázquez-Rosales ◽  
...  

2003 ◽  
Vol 41 (6) ◽  
pp. 2465-2470 ◽  
Author(s):  
M. K. Ghosh ◽  
L. Kuhn ◽  
J. West ◽  
K. Semrau ◽  
D. Decker ◽  
...  

2009 ◽  
Vol 83 (19) ◽  
pp. 10269-10274 ◽  
Author(s):  
Anne Piantadosi ◽  
Dana Panteleeff ◽  
Catherine A. Blish ◽  
Jared M. Baeten ◽  
Walter Jaoko ◽  
...  

ABSTRACT The determinants of a broad neutralizing antibody (NAb) response and its effect on human immunodeficiency virus type 1 (HIV-1) disease progression are not well defined, partly because most prior studies of a broad NAb response were cross-sectional. We examined correlates of NAb response breadth among 70 HIV-infected, antiretroviral-naïve Kenyan women from a longitudinal seroincident cohort. NAb response breadth was measured 5 years after infection against five subtype A viruses and one subtype B virus. Greater NAb response breadth was associated with a higher viral load set point and greater HIV-1 env diversity early in infection. However, greater NAb response breadth was not associated with a delayed time to a CD4+ T-cell count of <200, antiretroviral therapy, or death. Thus, a broad NAb response results from a high level of antigenic stimulation early in infection, which likely accounts for prior observations that greater NAb response breadth is associated with a higher viral load later in infection.


Neonatology ◽  
2007 ◽  
Vol 93 (3) ◽  
pp. 162-170 ◽  
Author(s):  
Habtom H. Habte ◽  
Corena de Beer ◽  
Zoë E. Lotz ◽  
Marilyn G. Tyler ◽  
Delawir Kahn ◽  
...  

2003 ◽  
Vol 77 (23) ◽  
pp. 12430-12440 ◽  
Author(s):  
Mark J. Geels ◽  
Marion Cornelissen ◽  
Hanneke Schuitemaker ◽  
Kiersten Anderson ◽  
David Kwa ◽  
...  

ABSTRACT Control of viremia in natural human immunodeficiency virus type 1 (HIV-1) infection in humans is associated with a virus-specific T-cell response. However, still much is unknown with regard to the extent of CD8+ cytotoxic T-lymphocyte (CTL) responses required to successfully control HIV-1 infection and to what extent CTL epitope escape can account for rises in viral load and ultimate progression to disease. In this study, we chose to monitor through full-length genome sequence of replication-competent biological clones the modifications that occurred within predicted CTL epitopes and to identify whether the alterations resulted in epitope escape from CTL recognition. From an extensive analysis of 59 biological HIV-1 clones generated over a period of 4 years from a single individual in whom the viral load was observed to rise, we identified the locations in the genome of five CD8+ CTL epitopes. Fixed mutations were identified within the p17, gp120, gp41, Nef, and reverse transcriptase genes. Using a gamma interferon ELIspot assay, we identified for four of the five epitopes with fixed mutations a complete loss of T-cell reactivity against the wild-type epitope and a partial loss of reactivity against the mutant epitope. These results demonstrate the sequential accumulation of CTL escape in a patient during disease progression, indicating that multiple combinations of T-cell epitopes are required to control viremia.


Sign in / Sign up

Export Citation Format

Share Document